{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:50:08Z","timestamp":1760061008718,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1163961"],"award-info":[{"award-number":["1163961"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jsat.2022.108871","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T02:52:49Z","timestamp":1662691969000},"page":"108871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Modeling the cost and impact of injectable opioid agonist therapy on overdose and overdose deaths"],"prefix":"10.1016","volume":"143","author":[{"given":"Wai Chung","family":"Tse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Dietze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jsat.2022.108871_bb0025","doi-asserted-by":"crossref","first-page":"690","DOI":"10.5694\/j.1326-5377.1996.tb122243.x","article-title":"The ACT heroin trial proposal: An overview. Australian Capital Territory","volume":"164","author":"Bammer","year":"1996","journal-title":"The Medical Journal of Australia"},{"issue":"6","key":"10.1016\/j.jsat.2022.108871_bb0035","doi-asserted-by":"crossref","first-page":"224","DOI":"10.24095\/hpcdp.38.6.02","article-title":"The opioid crisis in Canada: A national perspective. [La crise des opio\u00efdes au Canada : une perspective nationale]","volume":"38","author":"Belzak","year":"2018","journal-title":"Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice"},{"author":"Brooks","key":"10.1016\/j.jsat.2022.108871_bb0040"},{"issue":"4","key":"10.1016\/j.jsat.2022.108871_bb0045","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/add.12834","article-title":"A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia","volume":"110","author":"Burns","year":"2015","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.jsat.2022.108871_bb0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1192\/bjp.bp.112.111583","article-title":"Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction","volume":"203","author":"Byford","year":"2013","journal-title":"The British Journal of Psychiatry"},{"issue":"52","key":"10.1016\/j.jsat.2022.108871_bb0055","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.15585\/mmwr.mm6552a12","article-title":"QuickStats: Rates of drug overdose deaths involving heroin,* by selected age groups - United States, 2006\u20132015","volume":"65","author":"Centers for Disease Control","year":"2017","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.jsat.2022.108871_bb0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","article-title":"The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis","volume":"71","author":"Ciccarone","year":"2019","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.jsat.2022.108871_bb0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2018.09.007","article-title":"Understanding the use of diverted buprenorphine","volume":"193","author":"Cicero","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.jsat.2022.108871_bb0075","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","article-title":"Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies","volume":"106","author":"Degenhardt","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2022.108871_bb0080","first-page":"41","article-title":"Why do heroin users refuse to participate in a heroin-assisted treatment trial?","volume":"16","author":"Demaret","year":"2014","journal-title":"Heroin Addiction and Related Clinical Problems"},{"issue":"2","key":"10.1016\/j.jsat.2022.108871_bb0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0376-8716(02)00063-7","article-title":"Bystander resuscitation attempts at heroin overdose: Does it improve outcomes?","volume":"67","author":"Dietze","year":"2002","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.jsat.2022.108871_bb0090","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0376-8716(03)00169-8","article-title":"Buprenorphine versus methadone maintenance: A cost-effectiveness analysis","volume":"71","author":"Doran","year":"2003","journal-title":"Drug and Alcohol Dependence"},{"author":"Drug Enforcement Agency","key":"10.1016\/j.jsat.2022.108871_bb0095"},{"key":"10.1016\/j.jsat.2022.108871_bb0100","article-title":"Heroin maintenance for chronic heroin-dependent individuals","volume":"12","author":"Ferri","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1016\/j.jsat.2022.108871_bb0105","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5694\/j.1326-5377.2002.tb04289.x","article-title":"Breaking the deadlock over an australian trial of injectable opioid maintenance","volume":"176","author":"Hall","year":"2002","journal-title":"The Medical Journal of Australia"},{"key":"10.1016\/j.jsat.2022.108871_bb0110","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) statement","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ [British Medical Journal]"},{"issue":"1\u20132","key":"10.1016\/j.jsat.2022.108871_bb0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","article-title":"Polydrug abuse: A review of opioid and benzodiazepine combination use","volume":"125","author":"Jones","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2022.108871_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108006","article-title":"Impact of methadone treatment initiated in jail on subsequent arrest","volume":"113","author":"Kelly","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"8","key":"10.1016\/j.jsat.2022.108871_bb0135","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1007\/s11606-020-05920-0","article-title":"Comparison of treatment options for refractory opioid use disorder in the United States and Canada: A narrative review","volume":"35","author":"Kimmel","year":"2020","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.jsat.2022.108871_bb9090","article-title":"As a doctor, I was taught \u2018first do no harm.\u2019 That\u2019s why I have concerns with the so-called \u2018safe supply\u2019 of drugs","author":"Lam","year":"2021","journal-title":"The Globe and Mail"},{"issue":"1","key":"10.1016\/j.jsat.2022.108871_bb0140","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1186\/s12889-017-4785-7","article-title":"Estimating the number of people who inject drugs in Australia","volume":"17","author":"Larney","year":"2017","journal-title":"BMC Public Health"},{"issue":"12","key":"10.1016\/j.jsat.2022.108871_bb0145","doi-asserted-by":"crossref","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","article-title":"Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: A systematic review","volume":"5","author":"Larney","year":"2017","journal-title":"The Lancet Global Health"},{"issue":"1","key":"10.1016\/j.jsat.2022.108871_bb0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1521-0391.2009.00007.x","article-title":"Benzodiazepines, methadone and buprenorphine: Interactions and clinical management","volume":"19","author":"Lintzeris","year":"2010","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2022.108871_bb0160","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"3","author":"Mattick","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2022.108871_bb0165","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1016\/j.jsat.2022.108871_bb0180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12954-018-0268-0","article-title":"The complex relation between access to opioid agonist therapy and diversion of opioid medications: A case example of large-scale misuse of buprenorphine in the Czech Republic","volume":"15","author":"Mrav\u010d\u00edk","year":"2018","journal-title":"Harm Reduction Journal"},{"issue":"1","key":"10.1016\/j.jsat.2022.108871_bb0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12954-015-0089-3","article-title":"Mortality in the Melbourne injecting drug user cohort study (MIX)","volume":"12","author":"Nambiar","year":"2015","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.jsat.2022.108871_bb0195","article-title":"Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: Findings from a cross-sectional study in three Australian cities","author":"Nielsen","year":"2020","journal-title":"Addiction"},{"issue":"8","key":"10.1016\/j.jsat.2022.108871_bb0200","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa0810635","article-title":"Diacetylmorphine versus methadone for the treatment of opioid addiction","volume":"361","author":"Oviedo-Joekes","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.jsat.2022.108871_bb0210","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1001\/jamapsychiatry.2016.0109","article-title":"Hydromorphone compared with diacetylmorphine for long-term opioid dependence: A randomized clinical trial","volume":"73","author":"Oviedo-Joekes","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.jsat.2022.108871_bb0215","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/ADM.0000000000000505","article-title":"Adverse events during treatment induction with injectable diacetylmorphine and hydromorphone for opioid use disorder","volume":"13","author":"Oviedo-Joekes","year":"2019","journal-title":"Journal of Addiction Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2022.108871_bb0230","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1465-3362.2008.00015.x","article-title":"From illegal poison to legal medicine: A qualitative research in a heroin-prescription trial in Spain*","volume":"28","author":"Romo","year":"2009","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.jsat.2022.108871_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2019.106030","article-title":"Pregnant women in treatment for opioid use disorder: Material hardships and psychosocial factors","volume":"98","author":"Rose-Jacobs","year":"2019","journal-title":"Addictive Behaviors"},{"issue":"5152","key":"10.1016\/j.jsat.2022.108871_bb0240","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","article-title":"Drug and opioid-involved overdose deaths - United States, 2013\u20132017","volume":"67","author":"Scholl","year":"2018","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.jsat.2022.108871_bb0245","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ (Clinical Research Ed.)"},{"year":"2018","series-title":"Heroin-assisted treatment and supervised drug consumption sites: Experience from four countries","author":"Strang","key":"10.1016\/j.jsat.2022.108871_bb0255"},{"issue":"9729","key":"10.1016\/j.jsat.2022.108871_bb0260","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(10)60349-2","article-title":"Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): A randomised trial","volume":"375","author":"Strang","year":"2010","journal-title":"The Lancet"},{"key":"10.1016\/j.jsat.2022.108871_bb0265","series-title":"EMCDDA INSIGHTS. New heroin-assisted treatment. Recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond","volume":"Vol. 11","author":"Strang","year":"2012"},{"issue":"1","key":"10.1016\/j.jsat.2022.108871_bb0270","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","article-title":"Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction","volume":"207","author":"Strang","year":"2015","journal-title":"British Journal of Psychiatry"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222001532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222001532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:57:35Z","timestamp":1760039855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547222001532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":39,"alternative-id":["S0740547222001532"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108871","relation":{},"ISSN":["0740-5472"],"issn-type":[{"type":"print","value":"0740-5472"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling the cost and impact of injectable opioid agonist therapy on overdose and overdose deaths","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108871"}}